Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease?

Abstract

BMI appears to be important in predicting ADA efficacy (LOR) in CD. IFX appears to overcome this reduction of efficacy in obese patients. A prospective study evaluating the effect of weight on anti-TNF drug response and serum drug levels is warranted.